METHODS	In this 24-week , double-blind , phase IIb study , patients with active RA ( n = 507 ) were randomized to receive placebo or tofacitinib ( 20 mg/day , 1 mg twice daily , 3 mg twice daily , 5 mg twice daily , 10 mg twice daily , or 15 mg twice daily ) .\